Bimosiamose

Drug Profile

Bimosiamose

Alternative Names: BIMO; Bimosiamose disodium; TBC 1269; TBC 1269z

Latest Information Update: 20 Aug 2015

Price : $50

At a glance

  • Originator Encysive Pharmaceuticals
  • Developer Revotar Biopharmaceuticals
  • Class Anti-inflammatories; Antiasthmatics; Glycoconjugates; Hexanes; Skin disorder therapies; Small molecules
  • Mechanism of Action E-selectin inhibitors; L-selectin inhibitors; P selectin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Acute lung injury
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Discontinued Acute lung injury; Adult respiratory distress syndrome; Asthma; Chronic obstructive pulmonary disease; Plaque psoriasis

Most Recent Events

  • 28 Sep 2011 Final efficacy & adverse events data from a phase II trial in Chronic obstructive pulmonary disease presented at the 21st Annual Congress of the European Respiratory Society (ERS-2011)
  • 30 Mar 2011 Discontinued - Phase-II for Plaque psoriasis in Germany (Topical)
  • 30 Mar 2011 Discontinued - Phase-II for Plaque psoriasis in Germany (Intradermal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top